| Symbol | PULM |
|---|---|
| Name | PULMATRIX, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 945 CONCORD STREET,SUITE 1217, FRAMINGHAM, Massachusetts, 01701, United States |
| Telephone | +1 888 355-4440 |
| Fax | — |
| — | |
| Website | https://www.pulmatrix.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001574235 |
| Description | Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. Additional info from NASDAQ: |
New Form 10-K/A - Pulmatrix, Inc. <b>Filed:</b> 2026-06-16 <b>AccNo:</b> 0001493152-26-028902 <b>Size:</b> 4 MB
Read moreNew Form 425 - Pulmatrix, Inc. <b>Filed:</b> 2026-06-05 <b>AccNo:</b> 0001493152-26-027416 <b>Size:</b> 326 KB
Read moreNew Form S-3 - Pulmatrix, Inc. <b>Filed:</b> 2026-06-04 <b>AccNo:</b> 0001493152-26-027179 <b>Size:</b> 428 KB
Read moreNew Form SCHEDULE 13D - Pulmatrix, Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001104659-26-046851 <b>Size:</b> 28 KB
Read morePulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
Read moreNew Form D - Pulmatrix, Inc. <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 0001493152-26-016816 <b>Size:</b> 10 KB
Read morePULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05903612 | Allergic Bronchopulmonary Aspergillosis Prescreening Study | — | Allergic Bronchopulmonary Aspergillosis | Withdrawn | 2024-01-10 | 2024-01-10 | ClinicalTrials.gov |
| NCT05667662 | Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults Wit… | Phase2 | ABPA | Terminated | 2023-02-01 | 2024-02-27 | ClinicalTrials.gov |
| NCT05351086 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in … | Phase1 | Healthy | Completed | 2022-06-09 | 2022-09-22 | ClinicalTrials.gov |
| NCT04759807 | A Phase 1b Study of PUR1800 in Patients With COPD | Phase1 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2021-01-04 | 2021-12-02 | ClinicalTrials.gov |
| NCT03960606 | Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis | Phase2 | Allergic Bronchopulmonary Aspergillosis | Terminated | 2019-07-31 | 2020-07-14 | ClinicalTrials.gov |
| NCT03479411 | Safety, Tolerability and Pharmacokinetics of PUR1900 (Itraconazole Powder) in H… | Phase1 | Asthma | Completed | 2018-02-09 | 2018-06-28 | ClinicalTrials.gov |
| NCT02671825 | A PK Study to Evaluate PUR0200 and a Reference Product in Healthy Subjects | Phase1 | Healthy | Completed | 2016-01-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02280395 | A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety … | Phase1 | Postoperative Wound Infection-deep | Terminated | 2014-10-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02198963 | 21 Day Cumulative Skin Irritation of RUT058-60 | Phase1 | Irritation/Irritant | Completed | 2014-07-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01921712 | A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients | Phase1 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2013-07-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01690949 | Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Heal… | Phase1 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2012-08-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01543191 | A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis | Phase1 | Cystic Fibrosis | Completed | 2012-02-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01333904 | Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118 | Phase1 | Chronic Obstructive Pulmonary Disease | Completed | 2011-02-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01096173 | Determination of the in Vitro Effects of Cationic Airway Lining Modulators (CAL… | — | Chronic Obstructive Pulmonary Disease | Completed | 2010-04-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00989521 | Effect of PUR003 on Asthma | Phase1 | Asthma | Completed | 2009-12-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00947687 | Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Cha… | Phase1 | Healthy | Completed | 2009-07-01 | 2009-10-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00989521 |
| PUR003 | Other | Phase PHASE1 | Asthma | COMPLETED | NCT00989521 |
| PUR118 | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT01333904 |
| PUR118 | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT01690949 |
| PUR118 | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT01543191 |
| Active comparator | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT01921712 |
| PUR0200 Placebo | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT01921712 |
| PUR0200 | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT01921712 |
| 0.9% Physiological Saline, USP | Other | Phase PHASE1 | Irritation/Irritant | COMPLETED | NCT02198963 |
| 0.1% (w/v) Sodium Lauryl Sulfate | Other | Phase PHASE1 | Irritation/Irritant | COMPLETED | NCT02198963 |
| Hypochlorous acid solution 106 mg/L | Other | Phase PHASE1 | Irritation/Irritant | COMPLETED | NCT02198963 |
| Reference Product | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02671825 |
| PUR0200 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02671825 |
| Itraconazole 200 mg | Other | Phase PHASE1 | Asthma | COMPLETED | NCT03479411 |
| Itraconazole Powder | Other | Phase PHASE1 | Asthma | COMPLETED | NCT03479411 |
| Sterile saline for irrigation | Other | Phase PHASE1 | Postoperative Wound Infection-deep | TERMINATED | NCT02280395 |
| RUT058-60 | Other | Phase PHASE1 | Postoperative Wound Infection-deep | TERMINATED | NCT02280395 |
| Placebo | Other | Phase PHASE2 | Allergic Bronchopulmonary Aspergillosis | TERMINATED | NCT03960606 |
| PUR1900 | Other | Phase PHASE2 | Allergic Bronchopulmonary Aspergillosis | TERMINATED | NCT03960606 |
| PUR1800 500 ug | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT04759807 |
| PUR1800 250 ug | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT04759807 |
| Placebo Comparator | Other | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT04759807 |
| Matching Placebo for D.H.E 45 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05351086 |
| Matching Placebo for PUR3100 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05351086 |
| Dihydroergotamine (D.H.E 45) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05351086 |
| PUR3100 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05351086 |
| Placebo | Other | Phase PHASE2 | ABPA | TERMINATED | NCT05667662 |
| Itraconazole Powder | Other | Phase PHASE2 | ABPA | TERMINATED | NCT05667662 |
| Matching Placebo for D.H.E 45 | OTHER | Phase PHASE1 | Healthy | COMPLETED | NCT05351086 |
| Matching Placebo for PUR3100 | OTHER | Phase PHASE1 | Healthy | COMPLETED | NCT05351086 |
| Dihydroergotamine (D.H.E 45) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05351086 |
| PUR3100 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05351086 |
| PUR1800 500 ug | DRUG | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT04759807 |
| PUR1800 250 ug | DRUG | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT04759807 |
| Placebo Comparator | DRUG | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT04759807 |
| Itraconazole 200 mg | DRUG | Phase PHASE1 | Asthma | COMPLETED | NCT03479411 |
| Itraconazole Powder | DRUG | Phase PHASE2 | ABPA | TERMINATED | NCT05667662 |
| Reference Product | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02671825 |
| Sterile saline for irrigation | DRUG | Phase PHASE1 | Postoperative Wound Infection-deep | TERMINATED | NCT02280395 |
| RUT058-60 | DRUG | Phase PHASE1 | Postoperative Wound Infection-deep | TERMINATED | NCT02280395 |
| Active comparator | DRUG | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT01921712 |
| PUR0200 Placebo | DRUG | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT01921712 |
| PUR0200 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02671825 |
| 0.9% Physiological Saline, USP | DRUG | Phase PHASE1 | Irritation/Irritant | COMPLETED | NCT02198963 |
| 0.1% (w/v) Sodium Lauryl Sulfate | DRUG | Phase PHASE1 | Irritation/Irritant | COMPLETED | NCT02198963 |
| Hypochlorous acid solution 106 mg/L | DRUG | Phase PHASE1 | Irritation/Irritant | COMPLETED | NCT02198963 |
| PUR118 | DRUG | Phase PHASE1 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT01690949 |
| Placebo | DRUG | Phase PHASE2 | ABPA | TERMINATED | NCT05667662 |
| PUR003 | DRUG | Phase PHASE1 | Asthma | COMPLETED | NCT00989521 |